// App-Quantinova.ai

: HOUT-28. FIRST-LINE TEMOZOLOMIDE VS PCV FOR LOW GRADE GLIOMAS: A 11 YEARS REAL-WORLD DATA FROM CHUM, UNIVERSITY CENTER

Researchers

Presenter

  • Carole Lambert

Principal Investigators

  • Robert Moumdjian

  • France Berthelet

  • Meriem Ben-Abdallah

  • Jacques De Guise

  • Marie Florescu

Medical Centers

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • CRCHUM, Montreal, QC, Canada

  • CRCHUM, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Low-grade gliomas

Biomarkers

  • Hematocrit

Drug/Treatment

  • Temozolomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved